Table 1.

Variables included in hepatocellular carcinoma (HCC) risk scores (or associated with HCC) developed in individuals with chronic hepatitis B and in patients infected with HCV with advanced fibrosis who achieved virological clearance or control status following antiviral therapy.

			Variables Included in HCC Risk Scores for Virologically Controlled Patients Infected with HBV
Risk Score/Reference	Country or Area	Treatment	Host Factors			Liver Disease Activity		Cirrhosis/Fibrosis Parameters
			Age	Gender	Others	AFP	AST or ALT	PT	PLT	LSM	Albumin	Bilirubin
REACH-Bm [37]	Korea	Entecavir	X	X						NA	X
PAGE-B [38]	Europe	Entecavir/Tenofovir	X	X					X	NA
HCC-RESCUE [39]	Korea	Entecavir	X	X						NA
APA-B [40]	Taiwan	Entecavir	X			X			X	NA
CAMD [41]	Taiwan/Hong Kong	Entecavir/Tenofovir	X	X	Diabetes					NA
mPAGE-B [42]	Korea	Entecavir/Tenofovir	X	X					X	NA	X
AASL [43]	Korea	Entecavir/Tenofovir	X	X						X	X
			Variables Included in HCC Risk Scores for Patients Infected with HCV with Advanced Chronic Liver Disease Who Achieved Sustained Virological Response (SVR)
			Host factors			Liver disease activity		Cirrhosis/Fibrosis parameters
			Age	Gender	Others	AFP	AST or ALT	PT	PLT	LSM	Albumin	Bilirubin
van der Meer 2017 [19]	Europe	INF	X		Diabetes				X	NA
Calvaruso 2018 [29]	Italy	DAAs							X	NA	X
Ioannou 2018 [33]	USA	INF/DAAs	X				X		X	NA	X
Pons 2020 [34]	Spain	DAAs								X	X
Alonso Lopez 2020 [36]	Spain	DAAs								X	X
Audureau 2020 [44]	France	INF/DAAs	X				X	X		NA
			Variables included in HCC risk scores following HCV eradication or HBV control regardless of the cause of liver disease
			Host factors			Liver disease activity		Cirrhosis/Fibrosis parameters
			Age	Gender	Others	AFP	AST or ALT	PT	PLT	LSM	Albumin	Bilirubin
aMAP [45]	Worldwide	All regimens	X	X					X	NA	X	X

DAAs, direct antiviral agents; IFN, interferon; LSM, liver stiffness measurement; NA: non assessed; PLT, platelets; PT, prothrombin time.